Portugal
Technophage, SA, founded in 2005, is a pioneering force in biopharmaceutical innovation, focusing on the R&D of biological molecules in infection, neuroscience, and ophthalmology. With a strategic directive embodied in its slogan—"From Science to Innovative Biopharmaceuticals in Infection, Neuroscience and Ophthalmology"—the company anchors itself in extensive therapeutic development, carrying projects from early discovery stages through to clinical trials.
This Portugal-based company's recent establishment of its GMP manufacturing plant signifies a sustainable advance in producing key biologics, notably bacteriophages and antibody fragments, positioning it strategically within the biopharma and biotechnology industries. Its central operations near Santa Maria Hospital and the Instituto de Medicina Molecular João Lobo Antunes in Lisbon facilitate greater access to cutting-edge equipment and expert collaborations, further enriching its R&D endeavors.
Technophage's proactive partnership approach across Europe, the USA, and Asia underscores its commitment to expanding a robust pipeline of proprietary technologies and products, without any recent disclosures of external investment rounds.
